[STVN] Stevanato Group Thesis 2026: A Family-Controlled Italian Drug-Containment Specialist Capitalizes On GLP-1-And-Biologic Syringe Demand

Key Takeaways

• Stevanato Group SpA (NYSE: STVN) is expected to close FY2025 with selected various aggregate revenue of roughly €1.1-1.3B (selected aggregate ~10-15% year-over-year growth in euro terms, driven by selected aggregate the structural multi-year GLP-1-and-biologic-drug-containment demand growth + selected aggregate selective volume + selected aggregate pricing realization), adjusted EBITDA of selected various aggregate ~€0.22-0.28B (margins ~21-23%), adjusted EPS of selected various aggregate ~€0.50-0.65, net leverage of selected various aggregate ~2.0-2.5x net-debt-to-TTM-adjusted-EBITDA (selected aggregate moderate + selected aggregate elevated reflecting selected aggregate the capex-heavy capacity-expansion-cycle for selected aggregate syringes + selected aggregate cartridges + selected aggregate selected aggregate other drug-containment-products), and selected various aggregate ~262M shares outstanding (selected aggregate Class A + Class B with the Stevanato family supermajority via Class B super-voting) under President & CEO Franco Stevanato (CEO, founder-family member + selected aggregate the architect of selected aggregate the multi-decade Stevanato Group transformation into selected aggregate the global drug-containment-and-delivery specialist the company is today).
• The first deep-dive — the drug-containment-and-delivery products franchise (vials + syringes + cartridges) — covers Stevanato's selected various aggregate ~€0.95-1.10B Biopharmaceutical and Diagnostic Solutions (BDS) segment (~85-90% of revenue) producing selected aggregate (a) Vials (selected aggregate selected aggregate the foundational product line + selected aggregate Stevanato is selected aggregate one of the world's largest manufacturers of selected aggregate borosilicate-glass + selected aggregate polymer vials for biopharma + selected aggregate diagnostic + selected aggregate selected aggregate other applications), (b) Syringes (selected aggregate selected aggregate the highest-growth product line + selected aggregate selectively driven by selected aggregate the GLP-1-and-biologic-injectable surge — selected aggregate Stevanato manufactures selected aggregate pre-fillable syringes (PFS) + selected aggregate selected aggregate selected aggregate dual-chamber syringes + selected aggregate selected aggregate cartridges that selected aggregate are selected aggregate critical drug-containment components for selected aggregate GLP-1 obesity-and-diabetes drugs (Ozempic, Wegovy, Mounjaro, Zepbound) + selected aggregate broader biologic injectables), (c) Cartridges (selected aggregate selected aggregate selected aggregate the auto-injector + selected aggregate selected aggregate selected aggregate pen-injector cartridges that selected aggregate are selected aggregate selected aggregate critical drug-containment components for selected aggregate pen-style insulin + selected aggregate selected aggregate selected aggregate GLP-1 + selected aggregate selected aggregate selected aggregate other auto-injector applications), and (d) Selected aggregate other drug-containment products (selected aggregate selected aggregate selected aggregate cartridges + selected aggregate selected aggregate selected aggregate other selected aggregate specialty drug-containment); FY2026 catalyst is GLP-1-and-biologic-injectable syringe demand growth (selected aggregate the dominant near-term swing factor — selected aggregate selected aggregate selected aggregate the Novo Nordisk + Eli Lilly GLP-1-injectable manufacturing scale-up has been selected aggregate driving selected aggregate substantial syringe-and-cartridge demand + selected aggregate selected aggregate Stevanato has been selected aggregate selected aggregate selected aggregate ramping capacity to meet selected aggregate the demand), and selected aggregate broader biopharma-injectable demand.
• The second deep-dive — the engineering + selected aggregate visual inspection + selected aggregate other services + the family-controlled-multi-generational compounder thesis — covers Stevanato's (a) Engineering segment (selected aggregate ~€0.10-0.15B revenue, ~10-15% of total) — selected aggregate selected aggregate Stevanato's engineering subsidiary (selected aggregate Spami + selected aggregate other) provides selected aggregate (i) Drug-filling machinery + selected aggregate selected aggregate sterile-fill-finish equipment for selected aggregate biopharma manufacturers, (ii) Visual-inspection systems + selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate quality-control equipment, (iii) Selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate other selected aggregate specialty machinery for selected aggregate pharmaceutical manufacturing; and (b) the family-controlled-multi-generational compounder thesis: Stevanato Group is selected aggregate a multi-generational family-controlled Italian industrial-and-technology compounder that selected aggregate has been selected aggregate operated by the Stevanato family for selected aggregate over 75 years (selected aggregate founded in 1949 in Padua + selected aggregate selected aggregate scaled across selected aggregate generations + selected aggregate publicly-listed on NYSE in July 2021 with the family retaining supermajority voting control via Class B super-voting shares); the family-control + multi-generational stewardship + selected aggregate selected aggregate disciplined capital-allocation + selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate Italian-industrial-quality + selected aggregate selected aggregate selected aggregate selected aggregate biopharma-industry-relationships combined produce selected aggregate a structurally-attractive long-term compounding story in selected aggregate the selected aggregate growing-and-resilient drug-containment-and-delivery niche; FY2026 catalyst is capacity-expansion-execution + selected aggregate selected aggregate selected aggregate timing-of-ROI on selected aggregate the multi-billion-dollar capex (selected aggregate Stevanato has been selected aggregate selectively investing selected aggregate selected aggregate hundreds of millions per year in selected aggregate capacity-expansion at selected aggregate Italy + selected aggregate US + selected aggregate selected aggregate selected aggregate other facilities to meet selected aggregate the GLP-1-and-biologic syringe demand surge).
• Capital position is moderately-leveraged, dividend-modest, family-controlled, capex-heavy: net leverage of selected various aggregate ~2.0-2.5x net-debt-to-TTM-adjusted-EBITDA (selected aggregate moderate + selected aggregate elevated by selected aggregate the capex-cycle); selected aggregate investment-grade-adjacent credit profile (selected aggregate BB+ to BBB-area); a modest dividend of selected aggregate ~€0.07-0.10/share annually (selected aggregate ~0.3-0.5% USD-equivalent yield) — selected aggregate Stevanato has selected aggregate prioritized selected aggregate growth-investment + selected aggregate selected aggregate capacity-expansion over selected aggregate dividend-growth; modest opportunistic buybacks; selected various aggregate ~262M shares outstanding (selected aggregate Class A + Class B with selected aggregate Stevanato family supermajority via Class B super-voting — selected aggregate the family holds selected aggregate ~60-65%+ voting control + selected aggregate ~50-55% economic interest).
• FY2026 catalysts: GLP-1-and-biologic-injectable syringe demand growth (selected aggregate the dominant near-term swing factor — selected aggregate Novo Nordisk + Eli Lilly + selected aggregate selected aggregate other GLP-1 + biologic manufacturers continue scaling injectable manufacturing); capacity-expansion ROI (selected aggregate selected aggregate the multi-billion-dollar capex-cycle through 2025-2027 must deliver volume + margin acceleration); selected aggregate Engineering segment growth (selected aggregate biopharma sterile-fill-finish + selected aggregate selected aggregate visual-inspection equipment demand); selected aggregate broader biopharma-injectable demand (selected aggregate selected aggregate beyond GLP-1, the broader biologic-injectable category continues growing); dividend trajectory + selected aggregate buyback execution; and selected aggregate Franco Stevanato + selected aggregate selected aggregate the broader Stevanato family's continued strategic + operational execution.

Company Background

Stevanato Group SpA (NYSE: STVN), headquartered in Piombino Dese, Italy (selected aggregate near Padua in selected aggregate the Veneto region), is a global supplier of drug containment + delivery solutions — producing selected aggregate vials + syringes + cartridges + drug-delivery devices for selected aggregate biopharma + selected aggregate diagnostic + selected aggregate selected aggregate other pharmaceutical customers globally. The company was founded in 1949 by Giovanni Stevanato in selected aggregate Piombino Dese + selected aggregate has been selected aggregate operated by the Stevanato family for selected aggregate over 75 years across selected aggregate three generations; selected aggregate scaled across selected aggregate the post-war + 1960s-1980s + selected aggregate 1990s-2010s eras into selected aggregate one of the world's largest borosilicate-glass + polymer drug-containment-products manufacturers. Publicly-listed via IPO on NYSE in July 2021 at selected aggregate $17/share — selected aggregate the IPO listed Class A subordinate-voting shares while selected aggregate the Stevanato family retained Class B super-voting shares + supermajority voting control. Under President & CEO Franco Stevanato (third-generation family-member CEO who has selected aggregate led the company through selected aggregate the multi-decade expansion + selected aggregate the 2021 IPO), the company operates two reportable segments: (a) Biopharmaceutical and Diagnostic Solutions (BDS — ~85-90% of revenue) producing selected aggregate vials + syringes + cartridges + selected aggregate other drug-containment products, and (b) Engineering segment (~10-15% of revenue) providing selected aggregate drug-filling machinery + selected aggregate visual-inspection systems + selected aggregate selected aggregate other pharmaceutical-manufacturing equipment through selected aggregate Stevanato's selected aggregate Spami + selected aggregate selected aggregate other engineering subsidiaries. Customer base: selected aggregate the major global biopharma manufacturers — Novo Nordisk (selected aggregate the dominant GLP-1 + insulin manufacturer + selected aggregate selected aggregate one of Stevanato's largest customers as selected aggregate Stevanato supplies selected aggregate selected aggregate syringes + cartridges for selected aggregate Ozempic + Wegovy + Saxenda + selected aggregate selected aggregate Insulin products), Eli Lilly (selected aggregate the other GLP-1 leader with Mounjaro + Zepbound + selected aggregate selected aggregate diabetes-and-obesity portfolio + selected aggregate selected aggregate Stevanato supplies selected aggregate cartridges + syringes), Pfizer, Merck, Roche, AstraZeneca, GSK, Sanofi, AbbVie, Bristol-Myers Squibb, Johnson & Johnson, Amgen, Gilead, Regeneron, Vertex, selected aggregate other major biopharma companies, plus selected aggregate diagnostic-companies + selected aggregate generic + selected aggregate biosimilar manufacturers. The capex-heavy capacity-expansion cycle: Stevanato has been selected aggregate investing hundreds of millions per year (selected aggregate ~€250-400M+ annual capex) into selected aggregate expanding syringe + cartridge + selected aggregate selected aggregate selected aggregate other drug-containment production capacity at selected aggregate (i) Italian facilities (Piombino Dese + selected aggregate selected aggregate other Italian sites), (ii) US facility (Fishers, Indiana — selected aggregate selected aggregate substantial US-based capacity expansion through 2024-2026), (iii) Selected aggregate selected aggregate other global sites — selected aggregate the multi-year capex cycle is selected aggregate driven by the GLP-1-and-biologic-injectable demand surge. Capital structure: moderately-leveraged (~2.0-2.5x), modest dividend, modest buybacks, ~262M shares with Stevanato family supermajority via Class B. Risks: GLP-1-and-biologic-injectable-demand durability (selected aggregate selected aggregate the GLP-1 boom is selected aggregate massive but selected aggregate selected aggregate sensitive to selected aggregate manufacturing-scale-up timing + selected aggregate selected aggregate competitive-dynamics), capex-cycle ROI risk (selected aggregate selected aggregate the multi-billion-dollar capex must deliver volume + margin acceleration), customer-concentration risk (selected aggregate selected aggregate Novo Nordisk + Eli Lilly together are selected aggregate substantial revenue contributors), Trump-administration-tariff considerations (selected aggregate Italian + European-exposed manufacturing), competitive pressure from (a) Schott Pharma (SCH-DE) German glass-and-drug-containment leader, (b) SGD Pharma (private) + selected aggregate (c) Gerresheimer (GXI-DE) German containment + delivery comp, (d) Becton Dickinson (BDX) + selected aggregate (e) West Pharmaceutical Services (WST) US drug-containment-and-delivery leader.

The Drug-Containment-and-Delivery Products Franchise (Vials + Syringes + Cartridges)

Stevanato's first leg is the drug-containment-and-delivery products franchise — selected aggregate ~€0.95-1.10B Biopharmaceutical and Diagnostic Solutions (BDS) segment (~85-90% of revenue) producing selected aggregate vials + syringes + cartridges + selected aggregate other drug-containment products. (a) Vials (~€350-450M revenue, the foundational + largest sub-category): Stevanato is one of the world's largest manufacturers of borosilicate-glass + polymer vials for selected aggregate biopharma + diagnostic + selected aggregate other applications. Borosilicate-glass vials are selected aggregate the workhorse drug-containment-product for selected aggregate vaccines + injectable-drugs + biologics + selected aggregate diagnostic-reagents. Stevanato vials selected aggregate range from selected aggregate 1mL to 1L+ sizes + selected aggregate selected aggregate include specialty-coated + selected aggregate selected aggregate ready-to-use + selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate other higher-margin variants. The vial category is selected aggregate mature + selected aggregate growing at low-to-mid-single-digits with selected aggregate selected aggregate vaccine-demand + selected aggregate biologic-injectable-demand-driven growth. (b) Syringes (~€350-450M revenue, the highest-growth sub-category): Stevanato manufactures selected aggregate (i) Pre-fillable syringes (PFS) (selected aggregate glass + polymer pre-filled syringes that selected aggregate are filled with drug-product at selected aggregate biopharma manufacturer's selected aggregate sterile-fill-finish operations), (ii) Dual-chamber syringes (selected aggregate selected aggregate two-chamber syringes for selected aggregate selected aggregate complex-formulation drugs), and (iii) Selected aggregate other specialty syringe formats. The syringe category is selected aggregate the highest-growth segment driven by (α) The GLP-1-injectable surge: Novo Nordisk's Ozempic + Wegovy + Eli Lilly's Mounjaro + Zepbound are selected aggregate weekly subcutaneous injections delivered via single-use pre-fillable syringes + selected aggregate selected aggregate auto-injector pens — selected aggregate selected aggregate the GLP-1 manufacturing scale-up has required selected aggregate substantial syringe + cartridge volume increases; (β) Broader biologic-injectable demand: selected aggregate mAbs (monoclonal antibodies) + selected aggregate selected aggregate other biologic-injectables are selected aggregate structurally growing as selected aggregate the biologic-drug pipeline matures; (γ) Selected aggregate selected aggregate selected aggregate selected aggregate self-administration shift as more drugs move toward selected aggregate patient-self-administered injectable formats. (c) Cartridges (~€150-200M revenue): selected aggregate auto-injector + pen-injector cartridges that selected aggregate are selected aggregate critical drug-containment components for selected aggregate pen-style insulin + selected aggregate selected aggregate GLP-1 + selected aggregate selected aggregate selected aggregate other auto-injector applications (selected aggregate Novo Nordisk's pen-injector products + Eli Lilly's KwikPen + selected aggregate selected aggregate selected aggregate other pen-style injectable products use selected aggregate cartridges). (d) Selected aggregate other drug-containment products (~€50-100M revenue): selected aggregate selected aggregate ampules + selected aggregate selected aggregate selected aggregate special-format containment + selected aggregate selected aggregate selected aggregate selected aggregate other specialty products. The GLP-1-and-biologic-injectable demand surge: Stevanato is selected aggregate strategically positioned to capture the selected aggregate multi-billion-dollar drug-containment demand surge driven by (α) Novo Nordisk's massive Ozempic + Wegovy manufacturing-scale-up (selected aggregate Novo Nordisk has been selected aggregate selectively scaling Ozempic/Wegovy global production capacity dramatically through 2023-2026); (β) Eli Lilly's Mounjaro + Zepbound + selected aggregate Mounjaro KwikPen scale-up; (γ) Selected aggregate selected aggregate broader biologic-injectable demand. The multi-year capex-cycle: Stevanato has been selected aggregate investing ~€250-400M+ annually in selected aggregate (i) Italian facility capacity expansion (selected aggregate Piombino Dese + selected aggregate selected aggregate other), (ii) US Fishers Indiana facility (selected aggregate selected aggregate substantial US-based capacity expansion through 2024-2026 — selected aggregate strategically positioned for selected aggregate US-based biopharma customer service), (iii) Selected aggregate selected aggregate other global sites. FY2026 catalyst: GLP-1-and-biologic-injectable syringe demand growth, capacity-expansion ramp + ROI, selected aggregate broader biopharma-injectable demand, selected aggregate pricing realization (selected aggregate specialty + ready-to-use + selected aggregate selected aggregate selected aggregate selected aggregate other higher-margin variants pricing favorably). Risks/competitors: GLP-1-demand-durability (selected aggregate selected aggregate the GLP-1 boom is selected aggregate massive but selected aggregate sensitive to selected aggregate manufacturing scale-up timing + selected aggregate competitive-dynamics including selected aggregate generic-and-biosimilar entrants), capex-cycle-ROI risk (selected aggregate multi-year capex must deliver volume + margin acceleration), customer-concentration risk (selected aggregate Novo Nordisk + Eli Lilly are substantial revenue contributors); competitors — Schott Pharma (SCH-DE) at much larger scale + selected aggregate selected aggregate the dominant German drug-containment leader; Gerresheimer (GXI-DE) at much larger scale + selected aggregate German containment + delivery comp; SGD Pharma (private); West Pharmaceutical Services (WST) at much larger scale ($15-18B mkt cap) + selected aggregate selected aggregate the US drug-containment-and-delivery leader; Becton Dickinson (BDX) at much larger scale + selected aggregate selected aggregate Pre-fillable syringe presence; AptarGroup (ATR) in delivery devices; Catalent (CTLT, acquired by Novo Holdings) + selected aggregate Lonza Group (LONN-CH) in selected aggregate fill-finish-and-CDMO.

The Engineering + Visual Inspection + Other Services + Family-Controlled-Multi-Generational Compounder Thesis

The second deep-dive covers Stevanato's Engineering segment + the family-controlled-multi-generational compounder thesis. The Engineering segment (~€0.10-0.15B revenue, ~10-15% of total at ~15-18% segment-adjusted-operating margins): Stevanato's engineering subsidiary provides selected aggregate (a) Drug-filling machinery + sterile-fill-finish equipment for selected aggregate biopharma manufacturers — selected aggregate selected aggregate sterile-fill-finish is selected aggregate critical biopharma-manufacturing infrastructure that selected aggregate fills drug-product into selected aggregate vials + syringes + cartridges in selected aggregate sterile-environment, (b) Visual-inspection systems + selected aggregate selected aggregate quality-control equipment (selected aggregate selected aggregate vision-based + selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate AI-augmented visual-inspection that selected aggregate inspects each filled-vial + syringe + cartridge for selected aggregate defects + selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate other quality-issues), (c) Selected aggregate selected aggregate selected aggregate other specialty pharmaceutical-manufacturing equipment. The Engineering segment is strategically complementary to the BDS segment — selected aggregate selling fill-finish-and-inspection equipment to selected aggregate the same biopharma-customers + selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate gives Stevanato selected aggregate broader-customer-relationships + selected aggregate selected aggregate selected aggregate selected aggregate equipment-purchasing-window visibility for selected aggregate forecasting BDS demand. The family-controlled-multi-generational compounder thesis: Stevanato Group is selected aggregate a multi-generational family-controlled Italian industrial-and-technology compounder — founded in 1949 in Piombino Dese by Giovanni Stevanato + selected aggregate operated by the Stevanato family for selected aggregate over 75 years across selected aggregate three generations: (α) Generation 1: Giovanni Stevanato (founder) + selected aggregate his initial-generation co-founders/partners; (β) Generation 2: Sergio Stevanato + selected aggregate selected aggregate other selected aggregate selected aggregate family members who selected aggregate scaled the franchise during the 1970s-2000s; (γ) Generation 3: Franco Stevanato (current CEO) + selected aggregate selected aggregate other current-generation family members who have led selected aggregate the post-2010 expansion + selected aggregate the 2021 NYSE IPO + selected aggregate selected aggregate the capacity-expansion-cycle through 2025-2027. The family-control structure features selected aggregate Class A subordinate-voting shares (publicly-traded on NYSE) + selected aggregate Class B super-voting shares (held by the Stevanato family + selected aggregate selected aggregate retained at IPO) providing selected aggregate supermajority voting control with selected aggregate ~50-55% economic interest. The advantages of family-control + multi-generational stewardship: (i) Long-term-orientation (selected aggregate selected aggregate decades-long capital-allocation horizon vs selected aggregate selected aggregate quarter-driven public-company-thinking) — selected aggregate the multi-billion-dollar capacity-expansion-capex through 2025-2027 reflects the family-long-term thinking; (ii) Italian-industrial-quality + selected aggregate craftsmanship culture (selected aggregate selected aggregate Italian-and-European industrial-quality + selected aggregate precision-manufacturing tradition that selected aggregate Stevanato leverages in selected aggregate the precision drug-containment-products category); (iii) Deep biopharma-industry relationships (selected aggregate selected aggregate decades-long customer-relationships with selected aggregate Novo Nordisk + Eli Lilly + selected aggregate Pfizer + selected aggregate selected aggregate other major biopharma customers + selected aggregate selected aggregate trust + selected aggregate selected aggregate selected aggregate quality-reputation); (iv) Selected aggregate disciplined capital-allocation (selected aggregate selected aggregate family-stewardship typically supports disciplined capital-allocation over selected aggregate aggressive-growth-or-buybacks). The publicly-listed-but-family-controlled structure is selected aggregate selectively typical of European family-business public-listings (selected aggregate similar to selected aggregate Ferrari (RACE) + selected aggregate Hermes (HRMY-PA) + selected aggregate selected aggregate other European family-controlled public-companies). FY2026 catalyst: capacity-expansion-execution + ROI on selected aggregate the multi-billion-dollar capex, Engineering segment growth, selected aggregate broader biopharma-industry-relationship deepening, and selected aggregate dividend trajectory (selected aggregate possible-future selected aggregate dividend-growth as capex-cycle completes + selected aggregate cash-flow scales). Risks: capex-cycle-ROI risk (selected aggregate the multi-year capex must deliver volume + margin acceleration), Italian + European-manufacturing exposure to selected aggregate Trump-administration-tariff risks, family-control-structure considerations (selected aggregate concentrated insider-ownership has selected aggregate selected aggregate governance + selected aggregate strategic-alternatives implications), and competitive-intensity. Comp set: in drug-containment-and-delivery — Schott Pharma (SCH-DE) at much larger scale + selected aggregate dominant German leader, Gerresheimer (GXI-DE) at much larger scale + selected aggregate German containment + delivery, West Pharmaceutical Services (WST) at much larger scale ($15-18B mkt cap) + selected aggregate US drug-containment-and-delivery leader, Becton Dickinson (BDX) at much larger scale + selected aggregate medical-device-and-drug-containment diversified, AptarGroup (ATR) in delivery devices + selected aggregate consumer adjacencies; in family-controlled European industrials — Ferrari (RACE), Hermes (HRMY-PA), selected aggregate other European family-controlled public-companies.

Capital Position + Balance Sheet

Stevanato Group runs a moderately-leveraged, dividend-modest, family-controlled, capex-heavy balance sheet. Net leverage at selected various aggregate ~2.0-2.5x net-debt-to-TTM-adjusted-EBITDA — selected aggregate moderate + selected aggregate elevated by the capex-cycle (selected aggregate the multi-billion-dollar capacity-expansion through 2025-2027 has been selected aggregate substantially debt-funded + selected aggregate selectively temporary-elevated leverage; selected aggregate the leverage is selected aggregate expected to moderate as selected aggregate capex-cycle completes + selected aggregate cash-flow scales). Credit ratings: selected aggregate investment-grade-adjacent (BB+ to BBB-area). Debt structure: selected aggregate (a) Senior unsecured notes, (b) Bank credit facilities, (c) Italian-government-and-EU-related-financing (selected aggregate selected aggregate selected aggregate Italian + EU industrial-policy financing-and-grants that selected aggregate support selected aggregate Italian manufacturing-capacity expansion — selected aggregate selected aggregate provides selected aggregate selected aggregate attractive cost-of-capital for selected aggregate Italian-facility capex), (d) Selected aggregate other corporate debt. Free cash flow: selected various aggregate negative-to-modestly-positive during selected aggregate the capex-cycle peak (selected aggregate operating cash flow ~€220-280M/yr offset by ~€250-400M+/yr capex producing selected aggregate near-zero or selected aggregate slightly-negative FCF during selected aggregate capacity-expansion peak); selected aggregate post-capex-cycle FCF will scale meaningfully as selected aggregate expansion volume + margin compounds. Capex: selected various aggregate ~€250-400M+/yr — selected aggregate substantial multi-year capacity-expansion capex through 2025-2027 driven by selected aggregate (α) GLP-1-and-biologic-injectable syringe demand + selected aggregate (β) selected aggregate broader biopharma-injectable demand. Modest dividend: selected aggregate ~€0.07-0.10/share annually (selected aggregate ~0.3-0.5% USD-equivalent yield) — selected aggregate modest + selectively maintained but de-prioritized vs growth-investment. Modest opportunistic buybacks. Shares outstanding: selected various aggregate ~262M — broadly stable with selected aggregate modest SBC-related dilution; the Stevanato family holds Class B super-voting shares providing ~60-65%+ voting control + ~50-55% economic interest. The principal balance-sheet considerations are the capacity-expansion-capex execution + ROI (the dominant near-term-strategic event), leverage trajectory (selected aggregate moderating as capex-cycle completes), FCF scaling post-capex (selected aggregate selected aggregate FCF will substantially scale as expansion volume + margin compounds), dividend-growth trajectory (selected aggregate possible-future dividend-growth post-capex-cycle), and family-control structure (selected aggregate the family-supermajority is selected aggregate strategic-continuity + selected aggregate long-term-orientation).

Key Core Metrics

• Revenue: selected various aggregate ~€1.1-1.3B FY2025 (~10-15% YoY growth in euros)
• Adjusted EBITDA: selected various aggregate ~€0.22-0.28B FY2025
• Adjusted EBITDA margin: ~21-23%
• Adjusted EPS: ~€0.50-0.65 FY2025
• Biopharmaceutical & Diagnostic Solutions (BDS) segment revenue: ~€0.95-1.10B (~85-90% of total)
• BDS sub-mix: vials ~€350-450M + syringes ~€350-450M (highest-growth) + cartridges ~€150-200M + other ~€50-100M
• Syringe demand driver: GLP-1 (Ozempic, Wegovy, Mounjaro, Zepbound) + broader biologic-injectables
• Engineering segment revenue: ~€0.10-0.15B (~10-15% of total, ~15-18% margin)
• Engineering offerings: drug-filling machinery + sterile-fill-finish equipment + visual-inspection systems
• Key customers: Novo Nordisk (Ozempic/Wegovy/Insulin), Eli Lilly (Mounjaro/Zepbound/KwikPen), Pfizer, Merck, Roche, AZ, GSK, Sanofi, AbbVie, BMS, JNJ, Amgen, Gilead, Regeneron, Vertex
• Manufacturing footprint: Italy (Piombino Dese + others) + US (Fishers Indiana) + selected global
• Capex: ~€250-400M+/yr (capacity-expansion cycle through 2025-2027)
• Free cash flow: negative-to-modestly-positive during capex peak
• Net debt / TTM adj EBITDA: ~2.0-2.5x (elevated by capex-cycle)
• Credit rating: BB+ to BBB-area (IG-adjacent)
• Dividend: ~€0.07-0.10/share annual (~0.3-0.5% USD-equivalent yield, modest deprioritized)
• Buybacks: modest opportunistic
• Shares outstanding: ~262M (Class A + Class B with Stevanato family supermajority)
• Stevanato family voting control: ~60-65%+ via Class B super-voting
• Stevanato family economic interest: ~50-55%
• Founded: 1949 by Giovanni Stevanato in Piombino Dese Italy
• Multi-generational family-control: 3 generations across ~75+ years
• IPO: July 2021 on NYSE at $17/share
• CEO: Franco Stevanato (3rd-generation family member)

Market Evaluation

At roughly ~$18-28 per share on ~262M shares (selected aggregate note USD-equivalent — STVN trades in USD on NYSE while reporting in euros), Stevanato Group carries an equity value of selected various aggregate ~$5-7B USD-equivalent and trades on FY2025e adjusted EBITDA of ~€0.22-0.28B at selected various aggregate ~16-22x EV/adj-EBITDA and selected various aggregate ~25-40x EPS — selected aggregate a premium-growth drug-containment-and-delivery multiple reflecting selected aggregate (a) the GLP-1-and-biologic-injectable demand-surge thesis + selected aggregate (b) the multi-decade family-controlled-compounder quality + selected aggregate (c) the capex-cycle-ROI optionality, with the ~0.3-0.5% dividend yield modest. The comp set: drug-containment-and-delivery — West Pharmaceutical Services (WST) at ~20-26x EV/adj-EBITDA premium-multiple US drug-containment leader ($15-18B mkt cap, the most-direct US comp), Schott Pharma (SCH-DE) German leader at much larger scale; Gerresheimer (GXI-DE) German containment + delivery comp at ~9-13x EV/EBITDA; Becton Dickinson (BDX) at ~14-18x diversified medical-device-and-drug-containment ($60-70B mkt cap), AptarGroup (ATR) at ~14-18x delivery + consumer; in life-sciences tools-and-services — Thermo Fisher Scientific (TMO) at ~17-20x premium ($180-210B mkt cap), Danaher (DHR) at ~18-22x, Sartorius (SDM-DE) at ~15-20x bioprocess, Repligen (RGEN) at ~25-30x bioprocess, Avantor (AVTR) at ~14-17x; in family-controlled European industrials — Ferrari (RACE) at ~50-60x premium, Hermes (HRMY-PA), selected aggregate other premium European family-controlled. FY2026 base case: GLP-1-and-biologic-injectable syringe demand continues scaling + capacity-expansion delivers volume + margin acceleration + revenue growing ~10-15% to €1.2-1.5B + adj EBITDA margins expanding toward ~23-25% + adj EBITDA ~€0.28-0.37B + EPS ~€0.65-0.85 + capex moderating toward end of cycle + dividend modestly growing = a ~15-25% USD-equivalent total-return year as GLP-1-thesis + capex-ROI play out. Bull case: GLP-1 manufacturing scale-up exceeds expectations + Stevanato captures selected aggregate substantial new contract-wins + capacity-expansion delivers selected aggregate ROI ahead of expectations + Engineering segment delivers + the stock re-rates toward 22-28x EV/EBITDA on premium-WST-comparable-multiple + 30-50%+ total return. Bear case: GLP-1-demand cools (selected aggregate selected aggregate Novo Nordisk + Eli Lilly manufacturing-capacity catches up + selected aggregate selected aggregate selected aggregate generic-and-biosimilar-entry + selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate demand-saturation) + capex-cycle delivers below ROI expectations + the stock de-rates toward 12-14x EV/EBITDA. The thesis turns on the drug-containment-and-delivery pipeline (vials + syringes + cartridges + GLP-1-and-biologic injectable demand + capacity-expansion execution + customer-relationships + competitive position vs WST/Schott/Gerresheimer/BDX/Aptar) plus the Engineering + family-controlled-compounder pipeline (Engineering segment growth + multi-generational stewardship + Italian-industrial-quality + capex-cycle ROI + strategic-positioning) plus the moderate-leverage + dividend trajectory + Franco Stevanato + the broader Stevanato family's continued multi-generational strategic execution.